Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Evaluating Preclinical Performance of Novel Linker-Payloads to Widen ADC Therapeutic Index

Evaluating Preclinical Performance of Novel Linker-Payloads to Widen ADC Therapeutic Index

12:00 pm - Monday 12th October 2026

Explaining the impact of ADC innovation to improve and widen therapeutic index and potentially maximize patient benefit
Laying out MultiLINK novel linker-payload preclinical performance and mechanistic characterization to understand effect on tumor cells
Contextualizing novel linker-payload preclinical proof-of-concept to enhance ADC tolerability and therapeutic index

Speakers:

Noemie Luong

Noemie Luong

Associate Principal Scientist, Translational Pharmacology

Debiopharm